Pharma dynamics launches Zartan 50 mg — the first generic Angiotensin Receptor Blocker (ARB)

Pharma dynamics launches Zartan 50 mg — the first generic Angiotensin Receptor Blocker (ARB)

No abstract available.

Saved in:

Bibliographic Details
Main Author:	Editorial Office
Format:	Article
Language:	English
Published:	AOSIS 2007-10-01
Series:	South African Family Practice
Online Access:	https://safpj.co.za/index.php/safpj/article/view/975
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Launch of TAVALOXX 500mg and 750mg
by: Editorial Office
Published: (2008-02-01)

Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)
by: Kenichiro Kinouchi, et al.
Published: (2011-01-01)

The role of angiotensin II type 1 receptor pathway in cerebral ischemia‒reperfusion injury: Implications for the neuroprotective effect of ARBs
by: Shuhan Huang, et al.
Published: (2024-06-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Angiotensin receptor blockers: rational prescription tailored to the cardiovascular risk and comorbidities
by: V. I. Podzolkov, et al.
Published: (2018-12-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

POSSIBILITY OF ANGIOTENSIN RECEPTOR BLOCKERS IN OPTIMIZING OF ANTIHYPERTENSIVE PHARMACOTHERAPY IN PATIENTS AFTER STROK
by: Z M. Sizova
Published: (2015-09-01)

INHIBITION OF KIDNEY DISORDERS IN CARDIOVASCULAR DISEASES: THE ROLE OF ANGIOTENSIN II RECEPTOR BLOCKERS
by: V. V. Fomin
Published: (2016-01-01)

Clinical pharmacogenetics of angiotensin II receptor blockers: new perspectives of pharmacotherapy individualization
by: D. A. Sychev, et al.
Published: (2006-04-01)

Use of angiotensin receptor blockers in cardiovascular protection. Current evidence and future directions
by: M. A. Munger
Published: (1970-01-01)

Acoustic emission in compressed Mg-Li and Al alloys processed by ECAP, HPT and ARB methods
by: Andrzej Pawełek, et al.
Published: (2014-01-01)

A META-ANALYSIS REPORTING EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTSWITHOUT HEART FAILURE
by: G. Savarese, et al.
Published: (2015-09-01)

The impact of different angiotensin II receptor blockers on the stiffness of the large arteries and effectiveness of therapy
by: O. L. Rekovets, et al.
Published: (2022-12-01)

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
by: K. A. Ghyamdzhyan, et al.
Published: (2012-09-01)

Non‐genetic factors associated with ACE‐inhibitor and angiotensin receptor blocker‐induced angioedema
by: Diana Dubrall, et al.
Published: (2025-05-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: ISN'T IT TIME TO DRAW A LINE UNDER DISCUSSION ABOUT SUPERIORITY
by: S. Yu. Martsevich
Published: (2015-09-01)

Impact of Different Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blocker Resumption Timing on Post Acute Kidney Injury Outcomes
by: Jia-Jin Chen, et al.
Published: (2024-11-01)

The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
by: Mingfei Li, et al.
Published: (2021-01-01)

PROJECT-ORIENTED APPROACH TO FINISHED PHARMA PRODUCT DEVELOPMENT IN THE CONTEXT OF GENERIC POLYCOMPONENT DRUG CONTAINING AMOXYCILLIN AND CLAVULANIC ACID
by: Yu. V. Vlasenko
Published: (2019-01-01)

Comparison of platelet hemostasis effects for angiotensin receptor blockers in patients with arterial hypertension and metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2007-08-01)

Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients
by: Ali Kaan Güren, et al.
Published: (2025-04-01)

Effectiveness of an angiotensin II receptor blocker losartan as monoand combined therapy in hypertensive patients with various levels of renin-angiotensin-aldosterone system activity
by: Sh. V. Akhadov, et al.
Published: (2011-02-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

COMBINATION OF DIRECT RENNIN INHIBITOR - ALISKIREN, ANGIOTENSIN II RECEPTOR BLOCKER - VALSARTAN, AND CALCIUM CHANNEL BLOCKER - AMLODIPINE, IN THERAPY OF HYPERTENSIVE PATIENT WITH GOUT (CASE REPORT)
by: O. V. Dralova, et al.
Published: (2016-01-01)

Russia has launched the production of the world’s first combined tests
by: article Editorial
Published: (2021-07-01)

CordenPharma - The CDMO Partner You Need
by: David Spichiger
Published: (2025-05-01)

ACE Inhibitors and Angiotensin Receptor Blockers for the Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus
by: Neil Poulter
Published: (2025-02-01)

A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?
by: M. Greathouse
Published: (2011-10-01)

PHARMA SUPPLY CHAIN RESILIENCE. A SYSTEMATIC REVIEW
by: Balázs Bence Dienes, et al.
Published: (2024-06-01)

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in older adults with type 2 diabetes mellitus: a target trial emulation study
by: Weihong Zeng, et al.
Published: (2025-05-01)

The effect of the <i>M235T</i> polymorphism of the angiotensinogen gene on the office blood pressure during therapy with angiotensin II receptor blockers
by: E. V. Rebrova, et al.
Published: (2024-12-01)

Preoperative continuation vs. discontinuation of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on early cognitive function in elderly patients undergoing noncardiac surgery: a randomized controlled trial
by: Xiaohan Wang, et al.
Published: (2025-03-01)

Youth Should Be Part of African Pharma Industry—A Perspective
by: Samuel Inshutiyimana
Published: (2025-04-01)

Angiotensin receptor blockers use and lung cancer risk in Chinese patients with chronic obstructive pulmonary disease: a population-based cohort study
by: Wenhao Li, et al.
Published: (2025-05-01)

PATIENTS WITH COMBINATION OF CHRONIC HEART FAILURE, HYPERTENSION AND HISTORY OF MYOCARDIAL INFARCTION: CLINICAL AND ANAMNESTIC CHARACTERISTICS, ADMINISTRATION OF ACE INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, -BLOCKERS AND ADHERENCE TO THE DRUG THERAPY (DATA OF OUTPATIENT REGISTRY RECVASA)
by: M. M. Loukianov, et al.
Published: (2017-05-01)

Clamentin 1000 mg
by: Editorial Office
Published: (2007-10-01)

Difficult choice: angiotensin receptor antagonists
by: E. O. Taratukhin
Published: (2013-04-01)

Launch Notes
by: M. F. Thomsen
Published: (2022-12-01)

Efficacy and safety of ACEI/ARB drug plus Yishenhuashi Granule: a Meta-analysis
by: Zhao Qing, et al.
Published: (2021-01-01)